RPG Life Sciences Key Ratios
NSE: RPGLIFE | BSE: 532983
₹2,537.60
As on 28-Aug-2026IST
Market cap
₹4,187 Cr
Revenue (TTM)
₹734 Cr
P/E Ratio
35.1
P/B Ratio
6.6
Div. Yield
0.9 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 10.63 | 15.85 | 11.78 | 11.36 | 12.60 |
| EBIT | 38.89 | 24.23 | -1.31 | 13.40 | 17.35 |
| Net Profit | 5.12 | 16.28 | 23.11 | 17.71 | 21.25 |
| EPS | 2.24 | 16.28 | -34.64 | 18.64 | 21.82 |
| Book Value | -- | -- | 14.11 | 25.32 | 22.84 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 19.40 | 18.32 | 18.11 | 17.88 | 21.05 |
| Net Margin
| 19.34 | 16.54 | 15.74 | 15.71 | 27.44 |
| Return on equity
| 28.82 | 26.45 | 20.13 | 20.28 | 34.54 |
| Return on Capital
| 37.91 | 35.62 | -- | 26.99 | 44.20 |
| Return on Assets
| 22.02 | 19.93 | 16.47 | 15.89 | 27.90 |
| Debt to Equity (x)
| -- | -- | 0.02 | 0.03 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
26.99
|
51.79
|
34.96
|
32.92
|
|
Peer Median
|
--
|
15.48
|
16.46
|
15.49
|
--
|
ROE
20.13
Higher than Peers by 10.19
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
20.13
|
20.28
|
40.48
|
25.69
|
24.01
|
|
Peer Median
|
9.94
|
12.68
|
13.87
|
14.72
|
--
|
ROA
16.47
Higher than Peers by 9.21
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
16.47
|
15.89
|
31.35
|
18.82
|
17.71
|
|
Peer Median
|
7.26
|
7.69
|
8.04
|
7.19
|
--
|
EBIT Margin
18.11
Higher than Peers by 8.57
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
18.11
|
17.88
|
21.05
|
19.25
|
17.17
|
|
Peer Median
|
9.55
|
15.68
|
10.05
|
10.28
|
--
|
Net Margin
15.74
Higher than Peers by 7.11
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
15.74
|
15.71
|
27.44
|
14.88
|
13.07
|
|
Peer Median
|
8.64
|
11.16
|
9.11
|
6.78
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
18.06
|
29.21
|
16.79
|
14.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
11.78
Higher than Peers by 5.54
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
11.78
|
8.28
|
12.26
|
13.50
|
16.51
|
|
Peer Median
|
6.24
|
15.05
|
7.17
|
10.56
|
--
|
EBIT Growth
-1.31
Lower than Peers by 1.25
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
-1.31
|
-8.03
|
22.75
|
27.31
|
23.12
|
|
Peer Median
|
-0.06
|
19.88
|
12.05
|
6.17
|
--
|
Net Profit Growth
23.11
Higher than Peers by 15.53
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
23.11
|
-37.15
|
109.03
|
29.60
|
31.39
|
|
Peer Median
|
7.58
|
19.11
|
22.15
|
27.97
|
--
|
EPS Growth
-34.64
Lower than Peers by 36.83
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
-34.64
|
-37.15
|
109.03
|
29.60
|
31.39
|
|
Peer Median
|
2.18
|
23.11
|
8.80
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
14.11
|
41.53
|
21.86
|
20.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.02
Higher than Peers by 0.00
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
0.02
|
0.03
|
--
|
--
|
--
|
|
Peer Median
|
0.02
|
0.12
|
0.03
|
0.05
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.27
Higher than Peers by 0.82
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
3.27
|
3.27
|
3.88
|
2.28
|
2.57
|
|
Peer Median
|
2.45
|
2.48
|
2.20
|
1.93
|
--
|
Quick Ratio
2.50
Higher than Peers by 0.78
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
2.50
|
2.50
|
3.11
|
1.51
|
1.64
|
|
Peer Median
|
1.72
|
1.82
|
1.72
|
1.59
|
--
|
Interest Coverage
116.09
Higher than Peers by 106.38
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
116.09
|
88.12
|
147.47
|
82.83
|
80.72
|
|
Peer Median
|
9.71
|
13.67
|
12.28
|
12.45
|
--
|
Operating Efficiency
Debtors to sales
15.89
Lower than Peers by 11.02
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
15.89
|
16.49
|
13.28
|
8.44
|
7.30
|
|
Peer Median
|
26.91
|
30.65
|
26.23
|
23.97
|
--
|
Asset Turnover
1.01
Higher than Peers by 0.34
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
1.01
|
1.04
|
1.20
|
1.34
|
1.45
|
|
Peer Median
|
0.67
|
0.70
|
0.74
|
0.88
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
49.08
|
35.40
|
25.32
|
23.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
52.31
|
50.53
|
57.35
|
58.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
138.19
|
139.59
|
147.58
|
128.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
--
|
-36.81
|
-53.67
|
-64.92
|
-46.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
35.05
Lower than Peers by 20.02
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
35.05
|
26.57
|
20.56
|
28.87
|
17.01
|
|
Peer Median
|
55.07
|
55.07
|
39.17
|
40.74
|
--
|
Price / Book Value
6.58
Higher than Peers by 2.10
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
6.58
|
5.05
|
7.10
|
6.75
|
3.74
|
|
Peer Median
|
4.48
|
4.76
|
3.61
|
3.87
|
--
|
Dividend Yield
0.95
Higher than Peers by 0.80
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
0.95
|
1.30
|
1.05
|
1.05
|
1.72
|
|
Peer Median
|
0.15
|
0.15
|
0.19
|
0.20
|
--
|
EV/EBITDA
22.54
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
22.54
|
16.84
|
20.93
|
18.29
|
10.10
|
|
Peer Median
|
--
|
39.78
|
28.79
|
25.41
|
--
|
Market Cap
4,187
Lower than Peers by 1,633
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
RPG Life Sciences
|
4,187
|
3,060
|
3,767
|
2,531
|
1,151
|
|
Peer Median
|
5,820
|
5,820
|
3,944
|
2,959
|
--
|